Skip to content

Study on the effect and safety of ketogenic diet on metabolism of menopausal obese women

Study on the effect and safety of ketogenic diet on metabolism of menopausal obese women

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074950
Enrollment
Unknown
Registered
2023-08-21
Start date
2021-10-08
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopausal obese women

Interventions

Experimental group:Ketogenic diet in the first month, daily diet in the second month
Control group:Daily diet in the first month, ketogenic diet in the second month

Sponsors

Beijing Shijitan Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Female aged 40-60; (2) BMI>24kg/m2, body fat ratio>35%; (3) Having complete cognitive and reading and writing abilities; (4) Sign the informed consent form and voluntarily accept the health management of menopausal Ketogenic diet.

Exclusion criteria

Exclusion criteria: (1) Complicated with other malignant tumors, serious cardio cerebral Vascular disease, or other diseases leading to organ failure; (2) Patients with severe Complications of diabetes; (3) Patients who participate in other clinical trials within 3 months. (4) Diagnosed metabolic syndrome (5) Contraindications to Ketogenic diet: a. Metabolic contraindications: Carnitine deficiency, Carnitine palmitoyltransferase I or II deficiency, Carnitine transferase II deficiency ß- Oxidase deficiency, short chain acyl dehydrogenase deficiency, long chain 3-hydroxyacyl coenzyme deficiency, medium chain 3-hydroxyacyl coenzyme deficiency, Pyruvic acid hydroxylase deficiency, porphyria; b. Complicated contraindications: Urinary system stones, history of renal failure or severe renal insufficiency, familial Dyslipidemia, severe liver disease, chronic metabolic Acidosis, history of pancreatic disease, severe diabetes, active gallbladder disease, fat digestion disorder, severe cardio cerebral Vascular disease, etc; c. Contraindications of oral drugs: antiepileptic drugs such as zoxanide, topiramate and Acetazolamide can cause Acidosis, and treatment with Ketogenic diet will aggravate Acidosis; d. Special contraindications: Pregnant, lactating, currently infected, difficult to eat, and unable to cooperate with patients.

Design outcomes

Primary

MeasureTime frame
Blood fat;Weight;

Countries

China

Contacts

Public ContactWenpei Bai

Beijing Shijitan Hospital affiliated to Capital Medical University

baiwp@bjsjth.cn+86 10 6615 7805

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026